Law360, Los Angeles (April 1, 2013, 11:09 PM EDT) -- A Delaware federal judge on Saturday handed a win to Cephalon Inc. in its patent infringement suit aiming to block the sale of generic versions of the narcolepsy drug Nuvigil, rejecting generic-drug makers' claims that Cephalon's patent on the drug was invalid. U.S. District Judge Gregory M. Sleet held that generic-drug makers Apotex Corp., Sandoz Inc. and others had failed to show that an expired Cephalon patent, U.S. Patent Number 4,927,855, anticipated or made obvious the current Nuvigil patent, and barred the defendants from selling generic Nuvigil until after Cephalon's patent expires. “The court finds ... that the defendants have failed...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

Access to case data within articles (numbers, filings, courts, nature of suit, and more.)

Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.

Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS